Exhibit 99.1
Media Inquiries:
Lauren Barbiero
W2O Group
646-564-2156
lbarbiero@w2ogroup.com
Investor Inquiries:
Jim Goff
AveXis, Inc.
650-862-4134
jgoff@avexis.com
AveXis Announces Alignment with FDA on GMP Commercial Manufacturing Process for AVXS-101
— Agency is supportive of proposed analytical methods and comparability protocol —
— AveXis anticipates initiating U.S. SMA Type 1 and Type 2 trials in Q3 2017 with product from new process —
— AveXis manufacturing facility is fully operational for GMP product production —
— Conference call and webcast today at 4:30 p.m. EDT —
Chicago, Ill. (June 14, 2017) — AveXis, Inc. (NASDAQ: AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today announced alignment with the U.S. Food and Drug Administration (FDA) on the company’s Good Manufacturing Practice (GMP) commercial manufacturing process for AVXS-101 following the receipt of minutes from the Type B Chemistry Manufacturing and Controls (CMC) meeting. This alignment includes support for the proposed commercial manufacturing process, the proposed analytical methods and corresponding
qualification and validation plans — inclusive of key release assays such as potency, purity and identity — and the proposed comparability protocol, which helps assess how similar the product derived from the GMP process is to the original product used in the Phase 1 trial of AVXS-101 in patients with spinal muscular atrophy (SMA) Type 1.
Key components of the scalable, GMP commercial manufacturing process are as follows:
· AveXis will continue to utilize HEK293 cells and an adherent cell line.
· The commercial-scale GMP process will not include the use of Hyperstacks for AAV9 vector production.
1
